Novel synthetic bisbenzimidazole that targets angiogenesis in Ehrlich ascites carcinoma bearing mice

Roopashree, R. and Mohan, C. D. and Swaroop, T. R. and Jagadish, S. and Raghava, B. and Balaji, K. S. and Jayarama, S. and Basappa and Rangappa, K. S. (2015) Novel synthetic bisbenzimidazole that targets angiogenesis in Ehrlich ascites carcinoma bearing mice. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 25 (12). pp. 2589-2593.

Full text not available from this repository. (Request a copy)

Abstract

Cancer is a leading cause of death in developed countries and second cause in developing countries. Herein we are reporting the synthesis of novel bisbenzimidazole derivatives and their anticancer properties. Among the newly synthesized bisbenzimidazoles, 3-(4-flurophenylsulfonyl)-1,7-dimethyl-2-propyl-1H, 3H-2,5-bibenzod] imidazole (FDPB) presented as a potent antiproliferative agent against HeLa, HCT116 and A549 cells with selectivity over normal Vero cells (IC50 > 50 mu M). Additionally, we evaluated the efficacy of lead compound against Ehrlich ascites tumor (EAT) bearing mice for its antitumor and antiangiogenic properties. Our lead compound significantly reduced the cell viability, body weight, ascites volume and downregulated the formation of neovasculature and production of Vascular Endothelial Growth Factor (VEGF). (C) 2015 Elsevier Ltd. All rights reserved.

Item Type: Article
Uncontrolled Keywords: Bisbenzimidazole; Ehrlich ascites tumor; Angiogenesis; Antiproliferative; Vascular Endothelial Growth Factor; Micro vessel density
Subjects: C Chemical Science > Chemistry
Divisions: Department of > Chemistry
Depositing User: Shrirekha N
Date Deposited: 04 Jun 2019 10:04
Last Modified: 04 Jun 2019 10:04
URI: http://eprints.uni-mysore.ac.in/id/eprint/2349

Actions (login required)

View Item View Item